Roche CEO confident in breakthrough Alzheimer’s drug despite past failures

Q: How long will it take to read this news story?

The story "Roche CEO confident in breakthrough Alzheimer’s drug despite past failures" has 469 words across 16 sentences, which will take approximately 2 - 4 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Roche CEO confident in breakthrough Alzheimer’s drug despite past failures" was covered 13 hours ago by Business Mirror, a news publisher based in Philippines.

Q: How trustworthy is 'Business Mirror' news outlet?

Business Mirror is a fully independent (privately-owned) news outlet established in 2005 that covers mostly business and startups news. The outlet is headquartered in Philippines and publishes an average of 42 news stories per day. It's most recent story was published 10 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #23604182</li><li>URL: https://beamstart.com/news/roche-ceo-confident-in-breakthrough-17316887534834</li></ul>

Business Mirror Logo Business Mirror 13h ago

Roche CEO confident in breakthrough Alzheimer’s drug despite past failures - Business Mirror

Quick Summary:

Roche Holding AG is extremely optimistic that its latest experimental Alzheimer’s drug will deliver a benefit for patients, Chief Executive Officer Thomas Schinecker said, despite a track record of failures in the field.

In response, Schinecker pared the pipeline and pledged to move more quickly on promising projects, including a challenge to Novo Nordisk A/S in the growing market for obesity treatments.

The immediate revamp is done, and Roche is now “transitioning into more normal portfolio management and prioritization,” Schinecker said on a call with journalists.